We have previously shown that using the Elecsys total PSA assay, the ev-PSA/s-PSA ratio can differentiate prostate cancer patients from both benign prostatic hyperplasia patients and healthy controls (19). This evidence concerns the gene KLK3 and prostate carcinoma.